Page 28 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் தென்மேற்கு மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: Getty Images. HealthDay News Once-weekly insulin icodec is efficacious and well tolerated, according to 2 phase 2 studies published online in Diabetes Care. Ildiko Lingvay, MD, from the University of Texas Southwestern Medical Center in Dallas, and colleagues randomly assigned 205 insulin-naive adults with type 2 diabetes and hemoglobin A1c 7 to 10% while treated with oral glucose-lowering medications to once-weekly icodec titrations A (self-measured blood glucose target 80 to 130 mg/dL; adjustment ±21 units/week), B (80 to 130 mg/dL; ±28 units/week), or C (70 to 108 mg/dL; ±28 units/week) or to once-daily insulin glargine U100 (IGlar U100; 80 to 130 mg/dL; ±4 units/week). The percentage of time in range (TIR; 70 to 180 mg/dL) during weeks 15 and 16 was measured. The researchers found that from baseline to weeks 15 and 16, TIR improved in all groups. Compared with IGlar U100, TIR was greater for titration B (estimated treatment difference, 7.08%).

United statesUniversity of texas southwestern medical centerIldiko lingvayHarpreets bajajNovo nordiskHealthday newsTexas southwestern medical centerஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் தென்மேற்கு மருத்துவ மையம்டெக்சாஸ் தென்மேற்கு மருத்துவ மையம்